Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PMVP - PMV Pharmaceuticals, Inc.


1.23
0   0%

Share volume: 258,412
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%

$1.23
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
16%
Profitability 0%
Dept financing 28%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
-12.14%
3 Months
-21.66%
6 Months
-18.54%
1 Year
-24.54%
2 Year
-77.76%
Key data
Stock price
$1.23
P/E Ratio 
0.00
DAY RANGE
$1.20 - $1.28
EPS 
-$1.07
52 WEEK RANGE
$1.20 - $2.26
52 WEEK CHANGE
-$25.45
MARKET CAP 
78.138 M
YIELD 
N/A
SHARES OUTSTANDING 
51.520 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$216,975
AVERAGE 30 VOLUME 
$147,145
Company detail
CEO: David H. Mack
Region: US
Website: pmvpharma.com
Employees: 50
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PMV Pharmaceuticals, Inc. engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function.

Recent news